Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer

Human Pathology

Volumn 45, Issue 7, 2014, Pages 1509-1519

  McGrogan, Barbara ^a,c   Phelan, Sine ^a,b   Fitzpatrick, Patricia ^a   Maguire, Aoife ^a   Prencipe, Maria ^a   Brennan, Donal ^a,d   Doyle, Emma ^e   O'Grady, Anthony ^f   Kay, Elaine ^f   Furlong, Fiona ^g   McCann, Amanda ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c National Cancer Control Programme   (Ireland)

^d NATIONAL MATERNITY HOSPITAL   (Ireland)

^e ROTUNDA HOSPITAL   (Ireland)

^f BEAUMONT HOSPITAL   (Ireland)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

BUB1 related protein kinase (BUBR1); Chemotherapeutic agents; Ki 67; Mitotic arrest deficient 2 (MAD2); Ovarian cancer; Recurrence free survival (RFS); Spindle assembly checkpoint (SAC)

Indexed keywords

BUB1 RELATED PROTEIN; KI 67 ANTIGEN; PACLITAXEL; PLATINUM; PROTEIN MAD2;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; M PHASE CELL CYCLE CHECKPOINT; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY TUMOR; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY;

BUB1-RELATED PROTEIN KINASE (BUBR1); CHEMOTHERAPEUTIC AGENTS; KI-67; MITOTIC ARREST DEFICIENT 2 (MAD2); OVARIAN CANCER; RECURRENCE-FREE SURVIVAL (RFS); SPINDLE ASSEMBLY CHECKPOINT (SAC);

ADULT; AGED; CARCINOMA; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MAD2 PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL RATE; TIME FACTORS;

EID: 84903183613     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.03.004     Document Type: Article

References (37)

1. M. Harries, and M. Gore Part 1: chemotherapy for epithelial ovarian cancer - treatment at first diagnosis Lancet Oncol 3 2002 529 536 (Pubitemid 34993640)
2. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared to paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
3. B. McGrogan, B. Gilmartin, D.N. Carney, and A. McCann Taxanes, microtubules and chemoresistant breast cancer Biochim Biophys Acta 1785 2008 96 132
4. A. Mielgo, V.A. Torres, K. Clair, S. Barbero, and D.G. Stupack Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules Oncogene 28 2009 3551 3562
5. M. Li, X. Fang, Z. Wei, J.P. York, and P. Zhang Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice J Cell Biol 185 2009 983 994
6. Y. Fu, D. Ye, H. Chen, W. Lu, F. Ye, and X. Xie Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30 Gynecol Oncol 105 2007 66 73 (Pubitemid 46441441)
7. X. Hao, Z. Zhao, and S. Ye et al. Effect of MAD2 on paclitaxel-induced cell death in ovarian cancer cells Huazhong Univ Sci Technology Med Sci 30 2010 620 625
8. Y. Li, and R. Benezra Identification of a human mitotic checkpoint gene: hsMAD2 Science 274 1996 246 248
9. D.Y. Jin, F. Spencer, and K.T. Jeang Human T cell leukaemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1 Cell 93 1998 81 91 (Pubitemid 28173554)
10. S.S. Taylor, E. Ha, and F. McKeon The human homologue of Bub3 is required for kinetochore localisation of Bub1 and a Mad3/Bub1-related protein kinase J Cell Biol 142 1998 1 11 (Pubitemid 28341135)
11. G.K. Chan, S.A. Jablonski, V. Sudakin, J.C. Hittle, and T.J. Yen Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds at the cyclosome/APC J Cell Biol 146 1999 941 954 (Pubitemid 29430438)
12. A. Musacchio, and E.D. Salmon The spindle-assembly checkpoint in space and time Nature Reviews Mol Cell Biol 8 2007 379 393 (Pubitemid 46643240)
13. L.M. Greene, G. Campiani, M. Lawler, D.C. Williams, and D.M. Zisterer BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines Mol Pharmacol 73 2008 419 430 (Pubitemid 351159212)
14. T. Sudo, M. Nitta, H. Saya, and N.T. Ueno Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint Cancer Res 64 2004 2502 2508 (Pubitemid 38523906)
15. L.A. Malureanu, K.B. Jeganathan, M. Hamada, L. Walilewski, J. Davenport, and J.M. Van Deursen BubR1 N terminus acts as a soluble inhibitor of cyclin B degradation by APC/C (Cdc20) in interphase Dev Cell 16 2009 118 131
16. E. Burum-Auensen, P.M. De Angelis, A.R. Schjølberg, K.L. Kravik, M. Aure, and O.P. Clausen Subcellular localisation of the spindle proteins Aurora B, MAD2 and BUBR1 assessed by immunohistochemistry J Histochem Cytochem 55 2007 477 486 (Pubitemid 46668629)
17. Y. Yamamoto, H. Matsuyama, and Y. Chochi et al. Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer Cancer Genet Cytogenet 174 2007 42 47 (Pubitemid 46365984)
18. Y.K. Lee, E. Choi, M.A. Kim, P.G. Park, N.H. Park, and H. Lee BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancer Br J Cancer 101 2009 504 510
19. F. Furlong, P. Fitzpatrick, and S. O'Toole et al. Low MAD2 expression levels associate with reduced progression free survival in patients with high-grade serous epithelial ovarian cancer J Pathol 226 2012 746 755
20. S.H. Zhang, A.M. Xu, X.F. Chen, D.H. Li, M.P. Sun, and Y.J. Wang Clinicopathologic significance of mitotic arrest defective protein 2 overexpression in hepatocellular carcinoma Hum Pathol 39 2008 1827 1834
21. L. Wang, F. Yin, Y. Du, W. Du, B. Chen, and Y. Zhang MAD2 as a key component of mitotic checkpoint: a probable prognostic factor for gastric cancer Am J Clin Pathol 131 2009 793 801
22. M.K. Fung, H.W. Cheung, H.L. Wong, H.F. Yuen, M.T. Ling, and K.W. Chan MAD2 expression and its significance in mitotic checkpoint control in testicular germ cell tumour Biochim Biophys Acta 1773 2007 821 832 (Pubitemid 46829442)
23. D.J. Brennan, S. Ek, and E. Doyle et al. The transcription factor Sox11 is a prognostic factor for improved recurrence free survival in patients with high-grade serous epithelial ovarian cancer Eur J Cancer 45 2009 1510 1517
24. S.G. Silverberg Histologic grading of epithelial ovarian carcinoma: a review and proposal Int J Gynae Path 19 2000 7 15 (Pubitemid 30010638)
25. L. Österberg, K. Levan, K. Partheen, J. Staat, K. Sundfeld, and G. Horvath High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma Cytogenet Genome Res 125 2009 8 18
26. E.M. Doyle, M. Foley, P. Kelehan, and E.E. Mooney Histological grading of epithelial ovarian cancers J Obstet Gynaecol 27 2007 71 74
27. A.I. Halliday Spindle checkpoint protein hMAD2 and histone H3 phophoserine 10 mitosis marker in pediatric solid tumors Anticancer research 26 2006 4687 4694
28. P.L. Kandalaft, and K.L. Chang Prognostic significance of the immunohistochemical analysis of cathepsin-D in low-stage breast cancer Cancer 71 1993 2756 2763 (Pubitemid 23120051)
29. M. Hisaoka, A. Matsuyama, and H. Hashimoto Aberrant MAD2 expression in soft-tissue sarcoma Pathol Int 58 2008 329 333 (Pubitemid 351677533)
30. J. Du, Q. Du, and Y. Zhang et al. Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A, cyclin A and cyclin E in invasive ductal breast carcinomas Histol Histopathol 26 2011 761 768
31. M. Pinto, J. Vieira, and F. Ribeiro et al. Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas Cell Oncol 30 2008 389 395
32. K.T. Kuo, B. Guan, and T. Feng et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas Cancer Res 69 2009 5267
33. H. Grabsch, S. Takeno, and W.J. Parsons et al. Overexpression of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in gastric cancer-association with tumour cell proliferation J Pathol 200 2003 16 22 (Pubitemid 36592631)
34. Y. Nakano, T. Sumi, and M. Teramae et al. Expression of the mitotic-arrest deficiency 2 is associated with chemotherapy resistance in ovarian serous adenocarcinoma Oncol Rep 28 2012 1200 1204
35. Y.C. Wu, W.Y. Yen, and L.H. Yih Requirement of a functional spindle checkpoint for arsenite-induced apoptosis J Cell Biochem 105 2008 678 687
36. H.W. Cheung, D.Y. Jin, M.T. Ling, Y.C. Wong, Q. Wang, and S.W. Tsao Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells Cancer Res 65 2005 1450 1458 (Pubitemid 40270174)
37. E. Choi, and H. Lee Chromosome damage in mitosis induced BubR1 activation in prometaphase arrest FEBS letters 582 2008 1700 1706